AIM: To develop an immunomagnetic assay for the isolation of circulating tumor cells (CTCs) followed by the analysis of a multimarker panel, which will enable the characterization of these malignant cells with high accuracy. PATIENTS AND METHODS: Peripheral blood (PB) was collected from 32 metastatic breast cancer patients and 42 negative controls. The antibodies BM7 and VU1D9 were used for immunomagnetic tumor cell enrichment. A real-time reverse transcription-polymerase chain reaction (RT-PCR) approach for the markers KRT19, SCGB2A2, MUC1, EPCAM, BIRC5 and ERBB2 was used for CTC detection and characterization. RESULTS: THE POSITIVITY RATES FOR EACH MARKER WERE AS FOLLOWS: 46.9% for KRT19, 25.0% for SCGB2A2, 28.1% for MUC1, 28.1% for EPCAM, 21.9% for BIRC5, and 15.6% for ERBB2. After the creation of individualized cutoffs, the sensitivity and specificity of the combined marker gene panel increased to 56.3% and 100%, respectively. Interestingly, 27.0% of the HER2-negative tumor patients showed ERBB2 mRNA-positive CTCs. CONCLUSIONS: The described technique can be used to measure CTCs with great accuracy. The use of a multimarker panel for the characterization of CTCs may provide real-time information and be of great value in therapy monitoring.
AIM: To develop an immunomagnetic assay for the isolation of circulating tumor cells (CTCs) followed by the analysis of a multimarker panel, which will enable the characterization of these malignant cells with high accuracy. PATIENTS AND METHODS: Peripheral blood (PB) was collected from 32 metastatic breast cancerpatients and 42 negative controls. The antibodies BM7 and VU1D9 were used for immunomagnetic tumor cell enrichment. A real-time reverse transcription-polymerase chain reaction (RT-PCR) approach for the markers KRT19, SCGB2A2, MUC1, EPCAM, BIRC5 and ERBB2 was used for CTC detection and characterization. RESULTS: THE POSITIVITY RATES FOR EACH MARKER WERE AS FOLLOWS: 46.9% for KRT19, 25.0% for SCGB2A2, 28.1% for MUC1, 28.1% for EPCAM, 21.9% for BIRC5, and 15.6% for ERBB2. After the creation of individualized cutoffs, the sensitivity and specificity of the combined marker gene panel increased to 56.3% and 100%, respectively. Interestingly, 27.0% of the HER2-negative tumorpatients showed ERBB2 mRNA-positive CTCs. CONCLUSIONS: The described technique can be used to measure CTCs with great accuracy. The use of a multimarker panel for the characterization of CTCs may provide real-time information and be of great value in therapy monitoring.
Authors: Aliki Stathopoulou; Maria Ntoulia; Maria Perraki; Stella Apostolaki; Dimitris Mavroudis; Nikos Malamos; Vassilis Georgoulias; Evi S Lianidou Journal: Int J Cancer Date: 2006-10-01 Impact factor: 7.396
Authors: Narendra V Sankpal; Michael W Willman; Timothy P Fleming; John D Mayfield; William E Gillanders Journal: Cancer Res Date: 2009-01-13 Impact factor: 12.701
Authors: Paul N Span; Fred C G J Sweep; Erwin T G Wiegerinck; Vivianne C G Tjan-Heijnen; Peggy Manders; Louk V A M Beex; Jaques B de Kok Journal: Clin Chem Date: 2004-09-13 Impact factor: 8.327
Authors: Y Hiraga; S Tanaka; K Haruma; M Yoshihara; K Sumii; G Kajiyama; F Shimamoto; N Kohno Journal: Oncology Date: 1998 Jul-Aug Impact factor: 2.935
Authors: Ulrich Andergassen; Alexandra C Kölbl; Stefan Hutter; Klaus Friese; Udo Jeschke Journal: Cancers (Basel) Date: 2013-09-25 Impact factor: 6.639